Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield healthcare technology company, has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 24th issued US patent.
This new patent expands Aclarion’s proprietary rights to utilize magnetic resonance spectroscopy (MRS) to measure propionic acid (PA) as a biomarker for identifying potential sources of pain and infection throughout the body. Previous patents restricted the identification of PA to the intervertebral disc only.
“While propionic acid is a normal human physiological metabolite, there are many known side effects and disorders associated with propionic acid,” said Jeff Lotz, vice chair research, University of California at San Francisco. “Aclarion is a global leader in harnessing the power of MR spectroscopy, and this recent patent addition further expands the potential for Aclarion to commercialize the use of MRS beyond discogenic low back pain to encompass identifying and measuring propionic acid throughout the body. The implications are profound.”
MRS, a capability of leading magnetic resonance imaging (MRI) scanners, generates spectral data information on the levels of various biomarkers within the soft tissues. Conventional MRS post-processing methods often struggle to provide sufficient quality data for reliable chemical analysis. Aclarion’s patents address these challenges, resulting in enhanced reliability and quality of spectral data for chemical biomarker analysis, thereby ensuring accuracy and reliability in its Nociscan solution and other MRS applications.
